Applicant: Kaufmann, et al. Attorney's Docket No.: PP001656.0002 / 20366-144001

Serial No.: 09/758,575 Filed: January 9, 2001

Page : 2 of 15

Amendments to the Claims:

Please add new claim 49.

Please amend claims 46-48 as follows.

All amendments and cancellations to the claims are made without prejudice or disclaimer. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (**Previously presented**) An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
 - (a) a polynucleotide encoding amino acids from 1 to 273 of SEQ ID NO:2;
 - (b) a polynucleotide encoding amino acids from 2 to 273 of SEQ ID NO:2;
 - (c) a polynucleotide encoding amino acids from 26 to 273 of SEQ ID NO:2; and
 - (d) the polynucleotide complement of the complete polynucleotide of (a), (b), or (c).

Claims 2-4 (Cancelled)

- 5. (**Previously presented**) An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide wherein, except for no more than 5 conservative amino acid substitutions, said polypeptide has an amino acid sequence selected from the group consisting of:
 - (a) amino acids 1 to 273 of SEQ ID NO:2;
 - (b) amino acids 2 to 273 of SEQ ID NO:2; and
 - (c) amino acids 26 to 273 of SEQ ID NO:2;

wherein the encoded polypeptide is expressed at a higher level in metastatic cells relative to non-metastatic cells.

6. (Original) The isolated nucleic acid molecule of claim 1, which is DNA.

Applicant: Kaufmann, et al. Attorney's Docket No.: PP001656.0002 / 20366-144001

Serial No.: 09/758,575 Filed: January 9, 2001

Page : 3 of 15

7. (Previously presented) A method of making a recombinant vector comprising inserting a nucleic acid molecule of claim 1(a), (b), or (c), into a vector in operable linkage to a promoter.

- 8. (Original) A recombinant vector produced by the method of claim 7.
- 9. (Original) A method of making a recombinant host cell comprising introducing the recombinant vector of claim 8 into a host cell.
- 10. (Original) A recombinant host cell produced by the method of claim 9.
- 11. (**Original**) A recombinant method of producing a polypeptide, comprising culturing the recombinant host cell of claim 10 under conditions such that said polypeptide is expressed and recovering said polypeptide.

Claims 12-35 (Cancelled)

- 36. (**Previously presented**) An isolated nucleic acid molecule comprising a polynucleotide at least 95% identical to a polynucleotide selected from the group consisting of:
 - (a) a polynucleotide encoding amino acids from 1 to 273 of SEQ ID NO:2;
 - (b) a polynucleotide encoding amino acids from 2 to 273 of SEQ ID NO:2;
 - (c) a polynucleotide encoding amino acids from 26 to 273 of SEQ ID NO:2; and
- (d) the full polynucleotide complement of the complete polynucleotide of (a), (b), or (c); wherein the encoded polypeptide is expressed at a higher level in metastatic cells relative to non-metastatic cells.
- 37. (Previously presented) The isolated nucleic acid molecule of claim 36 wherein the polynucleotide is at least 98% identical to the polynucleotide of (a) (d).

Applicant: Kaufmann, et al. Attorney's Docket No.: PP001656.0002 / 20366-144001

Serial No.: 09/758,575 Filed : January 9, 2001 Page : 4 of 15

38. (Previously presented) A method of making a recombinant vector comprising inserting a nucleic acid molecule of claim 36 into a vector in operable linkage to a promoter.

- 39. (Previously presented) An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide at least 95% identical to SEQ ID NO:2, or the full complement of the complete polynucleotide, wherein the encoded polypeptide is expressed at a higher level in metastatic cells relative to non-metastatic cells.
- 40. (Previously presented) The isolated nucleic acid molecule of any one of claims 5, 36 or 39 wherein the encoded polypeptide is expressed at a level at least 2-fold greater in metastatic cells relative to non-metastatic cells.
- 41. (Previously presented) The isolated nucleic acid molecule of claim 39 wherein the polynucleotide encodes a polypeptide at least 98% identical to SEQ ID NO:2.
- 42. (Previously presented) The isolated nucleic acid molecule of any one of claims 5, 36 or 39 wherein the polynucleotide is at least 95% identical to SEQ ID NO:1.
- 43. (Previously presented) The isolated nucleic acid molecule of any one of claims 5, 36 or 39 wherein the polynucleotide is at least 98% identical to SEQ ID NO:1.
- 44. (Previously presented) The isolated nucleic acid molecule of claim 5 wherein the polynucleotide encodes a polypeptide wherein, except for no more than 3 conservative amino acid substitutions, said polypeptide has an amino acid sequence selected from the group consisting of:
 - (a) amino acids 1 to 273 of SEQ ID NO:2;
 - (b) amino acids 2 to 273 of SEQ ID NO:2; and
 - (c) amino acids 26 to 273 of SEQ ID NO:2.
- 45. (Previously presented) The isolated nucleic acid molecule of any one of claims 5, 36 or 39 wherein the nucleic acid molecule encodes a polypeptide comprising SEQ ID NO:10.

Applicant: Kaufmann, et al. Attorney's Docket No.: PP001656.0002 / 20366-144001

Serial No.: 09/758,575 Filed: January 9, 2001

Page : 5 of 15

46. (Currently amended) The isolated nucleic acid molecule of any one of claims 5, 36 or 39 wherein the the nucleic acid molecule encodes a polypeptide comprising SEQ ID NO:3.

- 47. (Currently amended) The isolated nucleic acid molecule of any one of claims 5, 36 or 39, said nucleic acid molecule comprising nucleotides 46-1173 446-1173 of SEQ ID NO:1.
- 48. (Currently amended) The isolated nucleic acid molecule of any one of claims 5, 36 or 39, said nucleic acid molecule comprising nucleotides 365-1173 of SEQ ID NO:1.
- 49. (New) The isolated nucleic acid molecule of claim 5 wherein the conservative substitutions are selected from the group consisting of:
- (a) leucine to isoleucine;
- (b) leucine to valine;
- (c) aspartate to glutamate; and
- (d) threonine to serine.